ArticleToxics2025
RNA-Seq Can Be Used to Quantify Gene Expression Levels for Use in the GARDskin Assay.
Article in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-animal methods for identification and characterization of skin sensitizers are continuously evolving, advancing towards more effective, accurate, and informational assays. The GARDskin assay is a scientifically and regulatory recognized assay for the assessment of skin sensitizers. It currently relies on targeted gene expression measurement to derive hazard classifications. With the progression of next generation sequencing technologies, whole transcriptome analysis provides an interesting alternative to the currently implemented targeted gene expression approach. RNA-seq was evaluated for its use in the GARDskin assay as a gene expression quantification method. Based on 24 paired samples acquired on both RNA-seq and the NanoString nCounter platform (the currently standard GARDskin acquisition method), gene expression profiles were found to be highly similar. Comparisons of treatment effects yielded a Spearman's correlation coefficient of 0.95 and a Lin's concordance correlation coefficient of 0.87. RNA-seq data was also used to classify the sensitizing hazard of 24 treatments using the standard GARDskin analysis pipeline. The classifications corresponded completely with references, rendering correct classifications for all treatments. In conclusion, it was found that the RNA-seq data strongly resembled NanoString nCounter data, and that it could be used to derive reliable hazard classifications in the GARDskin assay.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.